Verona Pharma plc (VRNA)
NASDAQ
Market Cap
$1.24B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
182 of 809
Rank in Industry
114 of 445
Largest Insider Buys in Sector
VRNA Stock Price History Chart
VRNA Stock Performance
About Verona Pharma plc
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Insider Activity of Verona Pharma plc
Over the last 12 months, insiders at Verona Pharma plc have bought $378,053 and sold $3.1M worth of Verona Pharma plc stock.
On average, over the past 5 years, insiders at Verona Pharma plc have bought $3.34M and sold $76.74M worth of stock each year.
Highest buying activity among insiders over the last 12 months: EBSWORTH DAVID R (director) — $316,080. Edwards Martin (director) — $123,946.
The last purchase of 33,736 shares for transaction amount of $61,973 was made by Edwards Martin (director) on 2023‑11‑20.
List of Insider Buy and Sell Transactions, Verona Pharma plc
| 2024-05-03 | Sale | Rickard Kathleen A. | Chief Medical Officer | 36,248 0.0058% | $1.96 | $71,032 | -14.73% | |
| 2024-02-05 | Sale | Rickard Kathleen A. | Chief Medical Officer | 36,248 0.0053% | $2.22 | $80,503 | -10.53% | |
| 2023-11-20 | Edwards Martin | director | 33,736 0.0053% | $1.84 | $61,973 | +9.16% | ||
| 2023-11-06 | EBSWORTH DAVID R | director | 160,000 0.0262% | $1.98 | $316,080 | +5.36% | ||
| 2023-11-03 | Sale | Rickard Kathleen A. | Chief Medical Officer | 58,752 0.0092% | $1.92 | $112,804 | +3.51% | |
| 2023-08-07 | Sale | ZACCARDELLI DAVID | President and CEO | 8,616 0.0014% | $2.47 | $21,263 | -15.47% | |
| 2023-08-07 | Sale | Hahn Mark W | Chief Financial Officer | 8,616 0.0014% | $2.47 | $21,263 | -15.47% | |
| 2023-08-07 | Sale | Rickard Kathleen A. | Chief Medical Officer | 1,600 0.0003% | $2.47 | $3,949 | -15.47% | |
| 2023-08-07 | Sale | Poll Claire | General Counsel | 1,512 0.0002% | $2.47 | $3,731 | -15.47% | |
| 2023-08-04 | Sale | ZACCARDELLI DAVID | President and CEO | 150,000 0.0237% | $2.50 | $374,880 | -19.22% | |
| 2023-08-04 | Sale | Hahn Mark W | Chief Financial Officer | 150,000 0.0237% | $2.50 | $374,880 | -19.22% | |
| 2023-08-04 | Sale | Rickard Kathleen A. | Chief Medical Officer | 27,944 0.0044% | $2.50 | $69,838 | -19.22% | |
| 2023-08-04 | Sale | Poll Claire | General Counsel | 26,352 0.0042% | $2.50 | $65,859 | -19.22% | |
| 2023-08-03 | Sale | ZACCARDELLI DAVID | President and CEO | 117,272 0.0187% | $2.54 | $297,754 | -19.61% | |
| 2023-08-03 | Sale | Hahn Mark W | Chief Financial Officer | 117,272 0.0187% | $2.54 | $297,754 | -19.61% | |
| 2023-08-03 | Sale | Rickard Kathleen A. | Chief Medical Officer | 50,600 0.0081% | $2.55 | $128,790 | -19.61% | |
| 2023-08-03 | Sale | Poll Claire | General Counsel | 20,608 0.0033% | $2.54 | $52,324 | -19.61% | |
| 2023-08-02 | Sale | ZACCARDELLI DAVID | President and CEO | 73,704 0.0116% | $2.59 | $191,114 | -21.88% | |
| 2023-08-02 | Sale | Hahn Mark W | Chief Financial Officer | 73,704 0.0116% | $2.59 | $191,114 | -21.88% | |
| 2023-08-02 | Sale | Rickard Kathleen A. | Chief Medical Officer | 13,728 0.0022% | $2.59 | $35,597 | -21.88% |
Insider Historical Profitability
61.86%
| ZACCARDELLI DAVID | President and CEO | 16431800 20.5552% | $14.69 | 0 | 18 | |
| Hahn Mark W | Chief Financial Officer | 15521248 19.4161% | $14.69 | 0 | 17 | |
| Rickard Kathleen A. | Chief Medical Officer | 2621552 3.4171% | $14.69 | 0 | 16 | |
| Poll Claire | General Counsel | 1907367 2.386% | $14.69 | 0 | 8 | |
| EBSWORTH DAVID R | director | 844643 1.0566% | $14.69 | 1 | 2 | |
| Edwards Martin | director | 144800 0.1811% | $14.69 | 1 | 2 | |
| Blavatnik Len | 55911648 69.942% | $14.69 | 1 | 0 | +61.86% | |
| Gupta Rishi | director | 3777778 4.7258% | $14.69 | 0 | 5 | |
| ORBIMED ADVISORS LLC | director | 3777778 4.7258% | $14.69 | 0 | 5 | |
| Ullman Anders | director | 334856 0.4189% | $14.69 | 0 | 2 | |
| Sinha Vikas | director | 74440 0.0931% | $14.69 | 0 | 2 | |
| SHAH MAHENDRA | director | 73080 0.0914% | $14.69 | 0 | 2 | |
| Deschamps Lisa | director | 70320 0.088% | $14.69 | 0 | 3 | |
| Cunningham Kenneth | director | 66584 0.0833% | $14.69 | 0 | 2 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| RA Capital Management, L.P. | $101.66M | 62.34 | 6.32M | 0% | +$0 | 0.1 | |
| Nea Management Company Llc | $89.86M | 50.4 | 5.11M | 0% | +$0 | 1.03 | |
| Wellington Management Company | $62.9M | 38.57 | 3.91M | +3.32% | +$2.02M | 0.01 | |
| Perceptive Advisors | $60.52M | 37.11 | 3.76M | -2.71% | -$1.68M | 0.04 | |
| Vivo Capital | $58.09M | 35.62 | 3.61M | -15.05% | -$10.29M | 5.12 | |
| OrbiMed | $54.67M | 33.53 | 3.4M | -10.05% | -$6.11M | 1.12 | |
| Deep Track Capital Lp | $51.29M | 31.45 | 3.19M | 0% | +$0 | 0.24 | |
| Frazier Life Sciences Management L P | $48.5M | 29.74 | 3.01M | 0% | +$0 | 2.49 | |
| The Carlyle Group | $39.44M | 24.25 | 2.46M | 0% | +$0 | 1.71 | |
| Octagon Capital Advisors LP | $38.12M | 23.37 | 2.37M | 0% | +$0 | 4.99 | |
| Federated Hermes | $36.34M | 22.29 | 2.26M | -9.42% | -$3.78M | 0.08 | |
| Eventide Asset Management | $35.2M | 21.58 | 2.19M | +58.77% | +$13.03M | 0.55 | |
| Janus Henderson | $32.66M | 20.05 | 2.03M | +12.68% | +$3.67M | 0.02 | |
| Maverick Capital Ltd | $28.57M | 17.52 | 1.78M | +7.2% | +$1.92M | 0.56 | |
| Fidelity Investments | $27.86M | 17.08 | 1.73M | -64.68% | -$51.02M | <0.01 | |
| JENNISON ASSOCIATES LLC | $25.64M | 15.73 | 1.59M | +0.53% | +$135,928.33 | 0.02 | |
| Caligan Partners LP | $20.86M | 12.79 | 1.3M | +608.19% | +$17.91M | 5.51 | |
| Bellevue Group | $18.33M | 11.24 | 1.14M | +35.63% | +$4.82M | 0.28 | |
| Aisling Capital Management LP | $17.95M | 11.01 | 1.12M | 0% | +$0 | 6.15 | |
| Hood River Capital Management LLC | $15.89M | 9.75 | 987,756 | +4.35% | +$662,167.86 | 0.36 | |
| Laurion Capital Management LP | $14.19M | 8.7 | 882,040 | +51.17% | +$4.8M | 0.4 | |
| Woodline Partners LP | $13.51M | 8.29 | 839,767 | +67.63% | +$5.45M | 0.13 | |
| Affinity Asset Advisors | $13.16M | 8.07 | 817,833 | +45.05% | +$4.09M | 2.34 | |
| Ally Bridge Group | $11.85M | 7.27 | 736,738 | New | +$11.85M | 6.67 | |
| Rice Hall James & Associates, LLC | $10.87M | 6.67 | 675,757 | +44.11% | +$3.33M | 0.66 | |
| Boothbay Fund Management LLC | $10.28M | 6.31 | 639,118 | +840.93% | +$9.19M | 0.35 | |
| American Century Investments | $9.02M | 5.53 | 560,859 | +5.88% | +$501,397.12 | 0.01 | |
| Parkman Healthcare Partners Llc | $8.52M | 5.23 | 529,520 | +4.91% | +$398,678.03 | 1.05 | |
| Millennium Management LLC | $8.11M | 4.97 | 504,073 | +31.49% | +$1.94M | 0.01 | |
| BlackRock | $6.14M | 3.77 | 381,717 | +4.69% | +$275,203.38 | <0.0001 | |
| Ikarian Capital LLC | $6.04M | 3.7 | 375,310 | +2.13% | +$126,177.78 | 1.72 | |
| Samsara Biocapital Llc | $5.59M | 3.43 | 347,500 | 0% | +$0 | 0.87 | |
| Morgan Stanley | $5.36M | 3.29 | 333,172 | -30.76% | -$2.38M | <0.0001 | |
| Moody Aldrich Partners, LLC | $5.07M | 3.11 | 314,912 | -1.95% | -$100,546.41 | 0.87 | |
| AXA | $4.47M | 2.74 | 277,784 | +0.03% | +$1,271.11 | 0.01 | |
| Schonfeld Group | $4.19M | 2.57 | 260,200 | -13.84% | -$672,562.00 | 0.03 | |
| ClearBridge Investments | $4.11M | 2.52 | 255,609 | +2.67% | +$106,917.95 | <0.01 | |
| Neuberger Berman | $3.45M | 2.11 | 214,231 | New | +$3.45M | <0.01 | |
| Tupelo Capital Management LLC | $3.22M | 1.97 | 200,000 | 0% | +$0 | 2.11 | |
| Prudential Financial | $2.84M | 1.74 | 176,756 | +23.8% | +$546,818.64 | <0.01 | |
| Adage Capital Partners Gp L L C | $2.82M | 1.73 | 175,000 | -73.16% | -$7.67M | 0.01 | |
| 1492 Capital Management, LLC | $2.64M | 1.62 | 164,263 | -1.07% | -$28,559.75 | 1.48 | |
| Citadel Advisors LLC | $2.29M | 1.4 | 142,212 | +404.48% | +$1.83M | <0.01 | |
| Two Sigma | $2.28M | 1.4 | 141,814 | +200.22% | +$1.52M | <0.01 | |
| Silverarc Capital Management Llc | $2.2M | 1.35 | 136,714 | New | +$2.2M | 0.65 | |
| Artia Global Partners Lp | $2.1M | 1.29 | 130,790 | 0% | +$0 | 0.52 | |
| Bank of America | $2.07M | 1.27 | 128,399 | +52.88% | +$714,605.20 | <0.0001 | |
| Kennedy Capital Management Inc | $1.98M | 1.22 | 123,215 | -25.62% | -$682,891.66 | 0.04 | |
| Polar Asset Management Partners Inc | $1.55M | 0.95 | 96,500 | 0% | +$0 | 0.03 | |
| Goldman Sachs | $1.49M | 0.92 | 92,780 | +131.56% | +$848,152.06 | <0.0001 |